Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries

András Inotai, Tamás Ágh, Alexei Willem Karpenko, Antal Zemplényi, Z. Kaló

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to Central and Eastern European (CEE) countries. Areas covered: After screening 376 abstracts, 42 articles were included in the final review. Statistical test results were rarely reported; therefore, the similarity of adverse event profiles of SCT and IVT could not be validated. Potential time savings for patients due to subcutaneous administration was not validated in CEE settings, where patient’s waiting time for treatment administration is fairly long. Standard patient reported outcome instruments were rarely used to confirm the preference of patients/health care professionals to SCT over IVT. Moreover, feasibility of self/home administration of SCT, especially in case of concomitant intravenous chemotherapies, was not considered. Cost comparisons considered neither the patent expiry of IVT nor the incremental cost of potential differences in adverse events. Expert commentary: Potential benefits of SCT were not tested by any studies in CEE countries. The main policy objective should be to facilitate the uptake of multisource biologicals in lower income countries with access barriers.

Original languageEnglish
JournalExpert Review of Pharmacoeconomics and Outcomes Research
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Costs and Cost Analysis
Trastuzumab
Patient Care
Economics
Breast Neoplasms
Delivery of Health Care
Drug Therapy
Therapeutics
Patient Reported Outcome Measures

Keywords

  • Breast cancer
  • intravenous
  • subcutaneous
  • transferability
  • trastuzumab

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

Behind the subcutaneous trastuzumab hype : evaluation of benefits and their transferability to Central Eastern European countries. / Inotai, András; Ágh, Tamás; Karpenko, Alexei Willem; Zemplényi, Antal; Kaló, Z.

In: Expert Review of Pharmacoeconomics and Outcomes Research, 01.01.2018.

Research output: Contribution to journalArticle

@article{93e262fb1c8844a484b7c02a5b304054,
title = "Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries",
abstract = "Introduction: Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to Central and Eastern European (CEE) countries. Areas covered: After screening 376 abstracts, 42 articles were included in the final review. Statistical test results were rarely reported; therefore, the similarity of adverse event profiles of SCT and IVT could not be validated. Potential time savings for patients due to subcutaneous administration was not validated in CEE settings, where patient’s waiting time for treatment administration is fairly long. Standard patient reported outcome instruments were rarely used to confirm the preference of patients/health care professionals to SCT over IVT. Moreover, feasibility of self/home administration of SCT, especially in case of concomitant intravenous chemotherapies, was not considered. Cost comparisons considered neither the patent expiry of IVT nor the incremental cost of potential differences in adverse events. Expert commentary: Potential benefits of SCT were not tested by any studies in CEE countries. The main policy objective should be to facilitate the uptake of multisource biologicals in lower income countries with access barriers.",
keywords = "Breast cancer, intravenous, subcutaneous, transferability, trastuzumab",
author = "Andr{\'a}s Inotai and Tam{\'a}s {\'A}gh and Karpenko, {Alexei Willem} and Antal Zempl{\'e}nyi and Z. Kal{\'o}",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/14737167.2019.1554437",
language = "English",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Behind the subcutaneous trastuzumab hype

T2 - evaluation of benefits and their transferability to Central Eastern European countries

AU - Inotai, András

AU - Ágh, Tamás

AU - Karpenko, Alexei Willem

AU - Zemplényi, Antal

AU - Kaló, Z.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to Central and Eastern European (CEE) countries. Areas covered: After screening 376 abstracts, 42 articles were included in the final review. Statistical test results were rarely reported; therefore, the similarity of adverse event profiles of SCT and IVT could not be validated. Potential time savings for patients due to subcutaneous administration was not validated in CEE settings, where patient’s waiting time for treatment administration is fairly long. Standard patient reported outcome instruments were rarely used to confirm the preference of patients/health care professionals to SCT over IVT. Moreover, feasibility of self/home administration of SCT, especially in case of concomitant intravenous chemotherapies, was not considered. Cost comparisons considered neither the patent expiry of IVT nor the incremental cost of potential differences in adverse events. Expert commentary: Potential benefits of SCT were not tested by any studies in CEE countries. The main policy objective should be to facilitate the uptake of multisource biologicals in lower income countries with access barriers.

AB - Introduction: Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to Central and Eastern European (CEE) countries. Areas covered: After screening 376 abstracts, 42 articles were included in the final review. Statistical test results were rarely reported; therefore, the similarity of adverse event profiles of SCT and IVT could not be validated. Potential time savings for patients due to subcutaneous administration was not validated in CEE settings, where patient’s waiting time for treatment administration is fairly long. Standard patient reported outcome instruments were rarely used to confirm the preference of patients/health care professionals to SCT over IVT. Moreover, feasibility of self/home administration of SCT, especially in case of concomitant intravenous chemotherapies, was not considered. Cost comparisons considered neither the patent expiry of IVT nor the incremental cost of potential differences in adverse events. Expert commentary: Potential benefits of SCT were not tested by any studies in CEE countries. The main policy objective should be to facilitate the uptake of multisource biologicals in lower income countries with access barriers.

KW - Breast cancer

KW - intravenous

KW - subcutaneous

KW - transferability

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85058141093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058141093&partnerID=8YFLogxK

U2 - 10.1080/14737167.2019.1554437

DO - 10.1080/14737167.2019.1554437

M3 - Article

AN - SCOPUS:85058141093

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

ER -